Welcome to Wehale.life - website about asthma and COPD!
This section is intended for healthcare professionals in Ireland treating people with respiratory diseases. We offer you:
- Insights on the scientific research and development behind Bufomix (budesonide/formoterol) Easyhaler® therapy, the latest scientific publications and interviews of colleagues.
- Patient support materials for you to use and guide your patients with Easyhaler® DPI device.
- Patient benefits introduces the main benefits that Easyhaler® offers to patients and physicians.
- Product info contains essential information about Bufomix (budesonide/formoterol) Easyhaler® the ICS/LABA combination therapy
- On the Events you can find information on respiratory congresses, our educational events and key lectures of leading experts in pulmonology.
Read more
Read more
Insights
Easy to master
Preferred by patients
Improved outcomes
Switching to
Bufomix (budesonide/formoterol) Easyhaler® may improve disease control and health related quality of life
Insights
Accurate and consistent
Patients with asthma or COPD are able to efficiently use Easyhaler® regardless of age or disease severity
Insights
Easy to master
Accurate and consistent
Preferred by patients
Dry powder inhalers – how to minimise handling errors and ensure patient satisfaction
Insights
Accurate and consistent
Ability of patients with asthma to achieve correct inspiratory flow rates for different inhalers
Insights
Accurate and consistent
Assessing patient inspiratory flow rate for clinical efficacy with
Bufomix (Budesonide/Formoterol) Easyhaler®
Insights
Flexible solution
Easy to master
Accurate and consistent
Preferred by patients
Improved outcomes
Sustainable choice
Switching to the Easyhaler Device to control Asthma and COPD: A literature review
Insights
Sustainable choice
Let’s keep the planet breathing:
Bufomix (budesonide/formoterol) Easyhaler® is now fully carbon neutral
Insights
Preferred by patients
Improved outcomes
The importance of patient satisfaction, preference, and adherence to inhaler for long-term asthma control
Insights
Flexible solution
Improved outcomes
Bufomix (budesonide/formoterol) Easyhaler® Maintenance and Reliever Therapy: MART
Insights
Accurate and consistent
More asthma patients achieve the optimal inspiratory flow for high-resistance inhalers than for low-resistance inhalers
Insights
Accurate and consistent
Preferred by patients
Sustainable choice
Easy, convenient, and environmentally friendly asthma and COPD care with Easyhaler®
Insights
Flexible solution
Improved outcomes
Comprehensive asthma care with Bufomix (budesonide/formoterol) Easyhaler® maintenance and reliever therapy (MART)
Insights
Accurate and consistent
Inhaler technical features and patient education in supporting successful treatment of asthma and COPD
Read more
DATE OF PREPARATION: MAY 2023/EASYH-688(10)
FULL PRESCRIBING INFORMATION AVAILABLE HERE
For more information about Orion and Sustainability click here
